Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Published 2017 View Full Article

Authors

Keywords

cell cycle checkpoint kinase inhibitor; prexasertib; LY2606368; PARP inhibitor; olaparib

Journal

Oncotarget

Volume 8, Issue 67, Pages -

Publisher

Impact Journals, LLC

Online

2017-10-31

DOI

10.18632/oncotarget.22195

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now